https://pubmed.ncbi.nlm.nih.gov/27551496/
Imeglimin is the first in a new class of oral glucose-lowering agents, having recently completed its phase 2b trial. As Imeglimin did show a full prevention of...
endothelial cellimegliminhumandeathinhibiting